We previously reported that tumor genomic alterations (copy number aberrations (CNAs) and somatic mutations) are readily detected in circulating cfDNA extracted from blood of patients with SCLC, highlighting the potential of this liquid biopsy as a tumor surrogate12; however, genomic profiling has not mapped to the TF-based SCLC subtypes described above5. This evidence concerns the gene TF and neoplasm.